Cannabis-Like Drug From E-Therapeutics Tested in Cancer
Researchers will begin testing an experimental drug made from chemicals like those in cannabis on cancer patients at two U.K. hospitals, and they expect findings next year on whether the product is safe.
Cancer Research UK and a U.K. National Institute for Health Research agency will carry out the trial of dexanabinol, a product made by e-Therapeutics Plc, in 45 patients with solid tumors at hospitals in Newcastle-upon-Tyne and Leeds, England, the Newcastle-based biotechnology company said today in a statement. E-Therapeutics is funding the research, it said.
“The starting point for this trial was to map networks of proteins that appear to have a role in cancer, identify points at which these networks could be disrupted, and then see if there were existing drugs to target these points,” Ruth Plummer, clinical professor of experimental cancer medicine at Newcastle University, who is leading the trial, said in the statement.
Dexanabinol is made in a laboratory and is chemically related to compounds found in marijuana, e-Therapeutics said. The drug was originally developed for patients with severe head injuries, Plummer said. It lacks the psychological effects associated with cannabis.
The company is 47 percent owned by Invesco Ltd., according to data compiled by Bloomberg.
To contact the reporter on this story: Andrea Gerlin in London at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.